Promoters are shifting from selling to buying. With $4Bn deployed in 2026, three cash-rich firms offer premiums of up to…
Invest India facilitated $6.1 billion across 60 projects in FY26, generating over 31,000 jobs and signalling a shift toward high-value…
Shift toward niche, high-skill businesses is shaping investor strategy, with precision manufacturing and CDMO firms gaining traction despite smaller scale.
A look at some of the undervalued pharma stocks in India.
Sun Pharma may be the most exposed to US tariffs but a global buffer could quietly limit the real damage.
Pharma stocks fall as Nifty Pharma drops 3%. Sun Pharma, Cipla slide amid US tariff fears and export risk concerns.
A ₹1,000 crore market is set to grow 5x to ₹5,000 crore by 2030 as prices drop 40–50% post patent…
Monday watchlist, March 30: Track Sun Pharma, HDFC Bank and ICICI as market volatility surges; review key stock setups and…
India ramps up enforcement against unauthorised sale and promotion of GLP-1 weight-loss drugs after generics hit the market, with inspections…
An endurance question turned into a consumer nutrition business, Built through failed trials, a stalled export, and a restart in…
Following the patent expiry of semaglutide in India, leading pharma companies including Sun Pharma, Dr Reddy’s, Zydus, and Glenmark have…
Ozempic patent expiry has triggered a fresh pharma race in India. Sun Pharma, Cipla, and Dr Reddy’s are among 7…
A key US drug approval is putting this pharma stock back on the radar, with a global brokerage pointing to…
Biocon earns USFDA nod for Liraglutide injection, boosting its diabetes drug portfolio. Explore investment opportunities now!
This article explores the burgeoning intersection of India’s trade momentum and the logistics sector. With cumulative exports reaching $720.8 billion…
While Nifty Pharma giants struggle with regulatory headwinds and pricing pressures, two outliers are quietly catching the attention of smart…
Markets watchlist today, March 09: Nifty faces bearish pressure this March; watch HDFC Bank, SBI, Tata Steel, and Vedanta for…
India’s pharmaceutical industry could face losses of Rs 2,500–5,000 crore as Middle East tensions disrupt shipping routes and double freight…